Featured Story | By Nick Paul Taylor Scilex has moved to neutralize a threat to a product that is central to its upcoming SPAC merger, starting a legal case against Apotex to protect its lidocaine patch from a potential competitor. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Johnson & Johnson is a step closer to realizing its vision of creating an all-oral, once daily, fixed-duration treatment regimen for chronic lymphocytic leukemia (CLL) patients. The Big Pharma’s strategy advanced last week when the European Medicines Agency’s (EMA) drug review committee backed the candidate. read more By Nick Paul Taylor DermBiont’s bet on SeylanMED has delivered a win in phase 2. Twenty months after acquiring the topical drug candidate SM-020, DermBiont has linked the prospect to improved outcomes in people with benign tumors, causing the phase 2 clinical trial to meet its primary and secondary endpoints. read more By Zoey Becker Siga Technologies' oral smallpox antiviral, Tpoxx, is racking up orders as the monkeypox outbreak spreads. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In a year in which biopharma revenues increased dramatically, especially among companies that brought COVID-19 products to the market, many firms laid out eye-popping pay packages for their chief executives. Bookending this year's list are longtime CEOs who retired from powerhouse U.S. companies during the year—No. 1 Alex Gorsky of Johnson & Johnson and No. 15 Ken Frazier of Merck. read more By Teresa Carey This week on "The Top Line," we discuss why scientists say we need an Alzheimer's moonshot. We also talk about a controversial take on diversity during a panel at the BIO conference. Plus, we'll hear award-winning ads that tug at our heartstrings. read more Resources Sponsored By: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Blue Matter, strategic consultants in the life sciences Medical Affairs plays a critical role in generating insights to inform strategic decisions, but that role is changing. This paper explores why, and how MA teams can stay ahead of the curve. Sponsored By: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
